Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. QGEN
10. SPY

Go back to Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results

Myriad Genetics (MYGN) PT Raised to $37 at Needham & Company

February 6, 2019 8:05 AM EST

Needham & Company analyst Stephen Unger raised the price target on Myriad Genetics (NASDAQ: MYGN) to $37.00 (from $36.00) while maintaining a Strong Buy rating.

Unger commented, "We are updating our financial model for MYGN following last night's release of FY2Q19 results. Our... More

Myriad Genetics (MYGN) Misses Q2 EPS by 3c; Offers 3Q & FY19 EPS/Revenue Outlook

February 5, 2019 4:31 PM EST

Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.38, $0.03 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $216.8 million versus the consensus estimate of $216.73 million.

"This quarter we saw a return to revenue growth for our hereditary cancer business, an... More